

Vaccine Clinic Resource for Immunizers

***Disclaimer:** this Quick Reference is not intended to replace other product specific vaccine references. The document is intended as a quick reference for frequently referred to information. Please refer to the product monograph and vaccine specific resources for all current and complete information*

Title:	Hepatitis A Vaccine Quick Reference Guide
Effective Date:	June 2026
Approver:	Final

Hepatitis A Vaccine Resources:

Fact sheet

<https://www.gov.mb.ca/health/publichealth/factsheets/hepa.pdf>

Product Monograph

Hepatitis A:

HAVRIX <https://ca.gsk.com/media/6243/havrix.pdf>

VAQTA® https://pdf.hres.ca/dpd_pm/00019913.PDF

Eligibility Criteria

For the most up to date information on eligibility criteria refer to: <https://www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html>

Canadian Immunization Guide:

For additional guidance on contraindications, precautions and special populations refer to the vaccine specific section: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-6-hepatitis-a-vaccine.html>

Hepatitis A Vaccine			
Product	Storage and Handling	Eligibility Criteria	Recommendations for Use
<p>HAVRIX Hepatitis A virus, inactivated</p> <p>Format: HAVRIX 1440:</p> <ul style="list-style-type: none"> Single dose 1 mL prefilled syringes - Supplied in packages of 1 prefilled syringe <p>HAVRIX 720 Junior:</p> <ul style="list-style-type: none"> Single dose 0.5 mL prefilled syringes –Supplied in packages of 1 prefilled syringe <p>Potential Allergens: neomycin sulphate, formaldehyde Other Ingredients: aluminum, amino acids, disodium phosphate, monopotassium phosphate, polysorbate 20, potassium chloride, sodium chloride, water for injection</p>	<p>Storage: Refrigerated 2° to 8°C until expiry date on label.</p> <p>Do NOT freeze. Protect from light</p> <p>Handling: <u>Reconstitution NOT required.</u></p> <p>The syringe should be well shaken to obtain a slightly opaque, white suspension</p>	<ul style="list-style-type: none"> Manitoba’s Hepatitis A Outbreak Eligibility The hepatitis A outbreak in Manitoba continues to evolve. In addition to individuals who have contact with cases or common exposures, individuals residing in, working in, traveling to or receiving visitors from communities with a hepatitis A outbreak are eligible for the hepatitis A vaccine. Please visit: www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html for the most up-to-date outbreak hepatitis A vaccine eligibility criteria. Individuals ≥ 6 months with at least one of the following high-risk medical conditions are eligible to receive 2 doses (refer to Table 1: Dosages and Schedules for Hepatitis A containing Vaccines of the Canadian Immunization Guide : https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-6-hepatitis-a-vaccine.html#p4c5a5) <ul style="list-style-type: none"> Chronic renal disease or undergoing dialysis Chronic liver disease including people infected with hepatitis C and chronic hepatitis B carriers Non-malignant hematologic disorders including repeated replacement of plasma-derived clotting factors HIV-infection Hematopoietic stem cell transplant recipients (as per https://www.gov.mb.ca/health/publichealth/cdc/docs/immrecord_hsct.pdf Immunization Schedule) CAR T-cell therapy recipients (as per https://www.gov.mb.ca/health/publichealth/cdc/docs/immrecord_cart.pdf Immunization Schedule) Solid organ transplant candidates and recipients with chronic liver diseases (prior to transplant or 6 months post-transplant) Congenital immune deficiencies (B cell deficiency, T cell mixed defects, phagocytic and neutrophil disorders, complement deficiency) people experiencing homelessness people using drugs in ways that involve smoking, snorting or injecting, or who share equipment used for these activities (excludes drugs that are used as prescribed for therapeutic indications) gay, bisexual, and other men who have sex with men (gbMSM) 	<p>Regimen: 2 doses*</p> <p>Dosage:</p> <ul style="list-style-type: none"> Adults from 19 years onward – HAVRIX 1440 – 1 mL Children from 6 months up to and including 18 years of age HAVRIX 720 – 0.5 mL <p>Route: IM (1” 25g needle)</p> <p>Interval:</p> <ul style="list-style-type: none"> A booster dose is recommended at any time between 6 and 12 months after a single dose of HAVRIX(1440 or 720) in order to ensure long-term protection <p>Contraindications:</p> <ul style="list-style-type: none"> < 6 mos. of age History of anaphylaxis to the vaccine or its components
<p>VAQTA® Hepatitis A virus, purified inactivated</p> <p>Format: VAQTA® Adult:</p> <ul style="list-style-type: none"> Single dose vial containing 1 mL (50 U of hepatitis A virus protein) <p>VAQTA® Pediatric/ Adolescent:</p> <ul style="list-style-type: none"> Single dose vials containing 0.5 mL (25 U of hepatitis A virus protein) <p>Potential Allergens: neomycin sulphate, formaldehyde, latex (vial stopper) Other Ingredients: Amorphous aluminum hydroxy phosphate sulfate, sodium borate and sodium chloride, water for injection</p>	<p>Storage: Refrigerated 2° to 8°C until expiry date on label.</p> <p>Do NOT freeze. Protect from light</p> <p>Handling: <u>Reconstitution is NOT required.</u></p> <p>The vial should be well shaken to obtain a slightly opaque, white suspension</p>	<ul style="list-style-type: none"> people experiencing homelessness people using drugs in ways that involve smoking, snorting or injecting, or who share equipment used for these activities (excludes drugs that are used as prescribed for therapeutic indications) gay, bisexual, and other men who have sex with men (gbMSM) 	<p>Regimen: 2 doses*</p> <p>Dosage:</p> <ul style="list-style-type: none"> Adults from 18 years onward- VAQTA® 50U- 1 mL Children from 6 months up to and including 17years of age- VAQTA® 25U – 0.5 mL <p>Route: IM (1” 25g needle)</p> <p>Interval:</p> <ul style="list-style-type: none"> A booster dose is recommended at any time between 6 and 18 months after a single dose of VAQTA® 25U or 50 U in order to ensure long-term protection <p>Contraindications:</p> <ul style="list-style-type: none"> < 6 mos. of age History of anaphylaxis to the vaccine or its components

* Once an HAHB vaccine series is started, it is preferable to complete the series with an HAHB vaccine. Clients who meet eligibility criteria for both hepatitis A and hepatitis B may receive the combined hepatitis A and B vaccine to ensure full protection against both infections. Monovalent HA vaccine may be used to complete a HA series started with HAHB vaccine. Refer to Table 2 for options for completing a HA vaccine series in the Hepatitis A vaccines: Canadian Immunization Guide <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-6-hepatitis-a-vaccine.html#p4c5t1> . Havrix and VAQTA® are considered interchangeable for completing the series.